Franz F. Hefti July 2005 - PowerPoint PPT Presentation

Slide1 l.jpg
Download
1 / 17

The World of West Coast Biotech: Needs and Opportunities. Franz F. Hefti July 2005. How Many Jobs?. Biotech Employees in California: 225,000 Source: State of California, 2004 Employment Development Department. How Many Pharmacologists?. ¼ PhD Pharmacologists

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.

Download Presentation

Franz F. Hefti July 2005

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Slide1 l.jpg

The World of West Coast Biotech:

Needs and Opportunities

Franz F. Hefti

July 2005


How many jobs l.jpg

How Many Jobs?

Biotech Employees in California: 225,000

Source: State of California, 2004

Employment Development Department


How many pharmacologists l.jpg

How Many Pharmacologists?

¼ PhD Pharmacologists

~ 4000 positions in California


Technical skill needs l.jpg

Technical Skill Needs

Easy to recruit

  • Molecular Pharmacologists

  • only the very best

    Difficult to recruit

  • In vivo Pharmacologists

  • Behavioral Pharmacologists

  • Safety Pharmacologists and Toxicologists

  • Secondary functions:

    • Pharmacokinetics experts

    • Quality Assurance/Quality Control experts

    • Regulatory experts

    • Project managers


Knowledge of drug discovery l.jpg

Knowledge of Drug Discovery


Drug discovery and development l.jpg

Drug Discovery and Development

Genomic Info

xx

Studies ofDisease Mechanisms

Safety testing

Target

Human Studies

Phases 1,2,3

Lead

Initial Biologic

Animal studies

Drug

Drug Candidate

efficacy in animal models

pharmacokinetics


Molecule based neuropharmacology l.jpg

Molecule-based Neuropharmacology

Class of receptors/channels/transporters

Specific receptor/channel/transporter

Molecular biology

Can we link it to a disease?


Slide8 l.jpg

Disease-mechanism based Neuropharmacology: Example Alzheimer

Brain

Blood

APP

X

X

Ab

monomers

TOXIC

X

X

TOXIC

Neuron

Ab

aggregates

TOXIC

X

Activated microglia

Microglia


Questions addressed for each disease l.jpg

Questions Addressed for Each Disease

What do we know about the disease mechanism?

What are the current drugs?

  • How were they found?

  • What are their targets and how do they work?

  • Can we make them better?

    How do we find new targets?

  • small molecules or biologics?

    How are the drug candidates further developed?

  • Are there predictive animal models?

  • How do we translate to human trials?


Drug discovery l.jpg

Drug Discovery


Mindset needs l.jpg

Mindset Needs

Intellectual flexibility

Motivation


Understanding of industry l.jpg

Understanding of Industry

Intellectual Property

  • Patent filings

  • Confidentiality

    Company status

  • Publicly traded

  • Private, pre-IPO

  • Fully-owned subsidiary

    Compensation

  • salary and bonus

  • stock options

    Contract

  • ‘at will’ employment

    Recruitment mechanisms

  • Networking

  • Website announcements


Accept flexible job stability l.jpg

Accept “Flexible Job Stability”

David L. Sloane, Ph.D.

since 2004 Associate Director,

Rinat Neuroscience

2000 -2003 Sr. Scientist,

Chiron Corporation

1995- 2000 Scientist III

Targeted Genetics

1993- 1995 Scientist II

Syntex Research

1989-1993 Post-doc

UCSF


Be ready to move l.jpg

Be Ready to Move

SepracorBoston

Oxford University

UK

Servier

Paris, France

SIBIA,

Merck

San Diego

Bionomics

Adelaide, Australia

Mark Varney, Ph.D.

VP Pharmacology, Sepracor Inc.


Adjust to company evolution l.jpg

Adjust to Company Evolution

RINAT NEUROSCIENCE

IND: anti-NGF for pain

Foundation by A. Rosenthal

1982

1984

1986

1988

1990

1992

1994

1996

1998

2000

2002

2004

2006

Focus on cancer therapeutics

Formation Neurosci. Res. Dept.

GENENTECH

Rinat-Genentech partnership agreement on anti-NGF

Clinical studies with NGF in neuropathy

Start of neuroscience research


Ability to find life after the bench l.jpg

Ability to Find ‘Life After the Bench’

Project Management

Quality Control/Quality Assurance

Regulatory Affairs

  • Organizational skills

  • Interpersonal skills

  • Managerial skills


Summary l.jpg

Summary

Expert technical skills

Understanding of drug discovery and development

Motivation and intellectual flexibility

Understanding of industry

Ability to change and adjust

Willingness to move away from the bench


  • Login